NASDAQ:SRRK - Scholar Rock Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.31 +0.16 (+0.84 %) (As of 10/18/2018 04:00 PM ET)Previous Close$19.15Today's Range$18.53 - $19.8452-Week Range$13.09 - $27.02Volume21,100 shsAverage Volume68,910 shsMarket Capitalization$650.03 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy. It is also developing various product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company was founded in 2012 and is based in Cambridge, Massachusetts. Receive SRRK News and Ratings via Email Sign-up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:SRRK CUSIPN/A Webwww.scholarrock.com Phone857-259-3860 Debt Debt-to-Equity RatioN/A Current Ratio17.50 Quick Ratio17.50 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$370,000.00 Price / Sales1,317.26 Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees50 Outstanding Shares25,240,000Market Cap$650.03 million Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions What is Scholar Rock's stock symbol? Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK." How were Scholar Rock's earnings last quarter? Scholar Rock Holding Corp (NASDAQ:SRRK) announced its quarterly earnings results on Wednesday, August, 8th. The company reported ($1.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.85. View Scholar Rock's Earnings History. When is Scholar Rock's next earnings date? Scholar Rock is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Scholar Rock. What price target have analysts set for SRRK? 4 brokers have issued 1-year price targets for Scholar Rock's shares. Their forecasts range from $25.00 to $31.00. On average, they expect Scholar Rock's share price to reach $27.3333 in the next twelve months. This suggests a possible upside of 41.6% from the stock's current price. View Analyst Price Targets for Scholar Rock. What is the consensus analysts' recommendation for Scholar Rock? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scholar Rock. Who are some of Scholar Rock's key competitors? Some companies that are related to Scholar Rock include argenx (ARGX), Regenxbio (RGNX), Repligen (RGEN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Spark Therapeutics (ONCE), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Solid Biosciences (SLDB), Editas Medicine (EDIT), Audentes Therapeutics (BOLD), DBV TECHNOLOGIE/S (DBVT) and Adaptimmune Therapeutics (ADAP). Who are Scholar Rock's key executives? Scholar Rock's management team includes the folowing people: Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 53)Mr. Elan Z. Ezickson, COO & Head of Corp. Devel. (Age 54)Mr. Yung H. Chyung, Chief Medical Officer (Age 42)Ms. Rhonda M. Chicko, Chief Financial Officer (Age 52)Mr. Alan J. Buckler, Chief Scientific Officer (Age 58) When did Scholar Rock IPO? (SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. When does the company's lock-up period expire? Scholar Rock's lock-up period expires on Tuesday, November 20th. Scholar Rock had issued 5,360,000 shares in its initial public offering on May 24th. The total size of the offering was $75,040,000 based on an initial share price of $14.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company. How do I buy shares of Scholar Rock? Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Scholar Rock's stock price today? One share of SRRK stock can currently be purchased for approximately $19.31. How big of a company is Scholar Rock? Scholar Rock has a market capitalization of $650.03 million and generates $370,000.00 in revenue each year. Scholar Rock employs 50 workers across the globe. What is Scholar Rock's official website? The official website for Scholar Rock is http://www.scholarrock.com. How can I contact Scholar Rock? Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected] MarketBeat Community Rating for Scholar Rock (NASDAQ SRRK)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 44 (Vote Outperform)Underperform Votes: 42 (Vote Underperform)Total Votes: 86MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote "Outperform" if you believe SRRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/18/2018 by MarketBeat.com StaffFeatured Article: What is the S&P 500 Index?